Nuvalent Inc. (NASDAQ:NUVL) is one of the best high short interest stocks with huge upside potential. On June 24, Nuvalent ...

Onco360®, the nation’s leading independent specialty pharmacy, has added Augtyro™ (repotrectinib) manufactured by Bristol ...

Dizal will market sunvozertinib in the US under the Zegfrovy brand name, entering a market for EGFR inhibitors currently ...

BrightSpring Health Services Inc. (NASDAQ:BTSG) is a home and community-based healthcare services platform in the US that ...

Get the latest Nuvalent, Inc. (NUVL) stock news and headlines to help you in your trading and investing decisions.

The study has generated its first results in the ROS1-positive NSCLC cohort, with a 79% overall response rate in patients never previously treated with a ROS1-targeting TKI, made up of 6% complete ...

Its based on both the image_tools cam2image demos for ROS2 as well as the libuvc and usb_cam project for ROS1. Features CameraInfo available CompressedImage topic (see compressed images for ...

An investigational oral targeted therapy, zipalertinib (CLN-081), demonstrated meaningful tumor responses and a manageable safety profile in patients with advanced non-small cell lung cancer (NSCLC) ...

This package contains messages for representing data from GPS devices and algorithms for manipulating it. This branch converts the messages and algorithms in this repository to support ROS 2 Dashing.

Chasing rivals, Nuvalent to seek approval of targeted lung cancer drug New study results position Nuvalent to bring forward what it claims is a differentiated treatment for ROS1-positive lung cancer, ...